Watch TIL. Know when insiders buy.
One email the day a filing lands. Free.
TIL
Instil Bio, Inc.
7.03
−0.14 −1.95%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
81
PASS · shorts 81
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $47.7MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$30.3MNET CASH —52W 6.66 – 21.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$5.6M | −$4.3M | — | -0.63 | −$4.6M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$7M | −$4.2M | — | -0.62 | −$1.3M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$9.6M | −$8.2M | — | -1.17 | −$7.1M | — | — | Mar 27 |
| Q3 2025 · Sep 30 | — | — | — | −$15M | −$13.6M | — | -2.01 | −$10.6M | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$23.4M | −$21.4M | — | -3.24 | −$14.8M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$30.6M | −$28.2M | — | -4.32 | −$4.2M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$11.8M | −$11.9M | — | -1.82 | −$10.6M | $0 | −$10.6M | Mar 27 |
| Q3 2024 · Sep 30 | — | — | — | −$23.6M | −$23M | — | -3.54 | −$20.1M | $0 | −$20.1M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$14.1M | −$14.9M | — | -2.29 | −$10.6M | $0 | −$10.6M | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$24M | −$24.3M | — | -3.74 | −$14.4M | $0 | −$14.4M | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$13M | −$12.9M | — | -1.99 | −$13.4M | $58K | −$13.4M | Mar 4 |
| Q3 2023 · Sep 30 | — | — | — | −$66.7M | −$67.4M | — | -10.37 | −$14.4M | $5.2M | −$19.6M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$78.6M | −$71.4M | — | -10.70 | −$36.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$73.5M | −$74.1M | — | -11.39 | −$55.7M | $0 | −$55.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$159.2M | −$156.1M | — | -24.00 | −$82M | $20.7M | −$102.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$226.5M | −$223.2M | — | -34.46 | −$180.2M | $84.6M | −$264.8M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$155.6M | −$156.8M | — | -1.48 | −$122.1M | $57.8M | −$180M | — | — |
| FY2020 · to Dec 31 | $138K | — | −$33.6M | −$37.7M | -27346.4% | -2.36 | −$29.6M | $50.8M | −$80.4M | — | — |
Every number comes from Instil Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.